BRPI0506916A - modulação da chaperonina 10 da secreção de citocina e de quimiocina que pode ser induzida pelo receptor similar a toll - Google Patents

modulação da chaperonina 10 da secreção de citocina e de quimiocina que pode ser induzida pelo receptor similar a toll

Info

Publication number
BRPI0506916A
BRPI0506916A BRPI0506916-5A BRPI0506916A BRPI0506916A BR PI0506916 A BRPI0506916 A BR PI0506916A BR PI0506916 A BRPI0506916 A BR PI0506916A BR PI0506916 A BRPI0506916 A BR PI0506916A
Authority
BR
Brazil
Prior art keywords
toll
receptor
cpn10
secretion
induced
Prior art date
Application number
BRPI0506916-5A
Other languages
English (en)
Inventor
Barbara Jane Johnson
Dean Jason Naylor
Caroline Amanda Dobbin
Christopher Bruce Howard
Andreas Suhrbier
Original Assignee
Cbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004900190A external-priority patent/AU2004900190A0/en
Application filed by Cbio Ltd filed Critical Cbio Ltd
Publication of BRPI0506916A publication Critical patent/BRPI0506916A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MODULAçãO DA CHAPERONINA 10 DA SECREçãO DE CITOCINA E DE QUIMIOCINA QUE PODE SER INDUZIDA PELO RECEPTOR SIMILAR A TOLL. A presente invenção refere-se aos processos de uso da Chaperonina 10 (Cpn10) são fornecidos para a regulação do receptor similar a Toll e/ou da secreção do imunomodulador que pode ser induzida pelo receptor similar a Toll. A Cpn10 regula de forma negativa a secreção de citocina e de quimiocina pró-inflamatórias induzida pelo agonista do receptor similar a Toll, os exemplos sendo IL-6 e RANTES, respectivamente. A Cpn10 regula positivamente a secreção da citocina e da quimiocina antiinflamatórias induzida pelo agonista do receptor similar a Toll, um exemplo sendo IL-10. Estas atividades imunorreguladoras da Cpn10 podem ser úteis no tratamento de doenças, distúbios e estados de saúde resultantes da secreção excessiva da citocina e da quimiocina pró-inflamatórias. Esta invenção refere-se ainda à produção, ao planejamento e/ou à produção, ao planejamento e/ou à seleção de agonistas e de antagonistas de Cpn10 de acordo com sua capacidade de regular a sinalização do receptor similar a Toll e/ou a secreção do imunomodulador que pode ser induzido pelo receptor similar a Toll.
BRPI0506916-5A 2004-01-16 2005-01-14 modulação da chaperonina 10 da secreção de citocina e de quimiocina que pode ser induzida pelo receptor similar a toll BRPI0506916A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004900190A AU2004900190A0 (en) 2004-01-16 Chaperonin 10 modulation of cytokine and chemokine secretion
AU2004903914A AU2004903914A0 (en) 2004-07-16 Chaperonin 10 modulation of cytokine and chemokine secretion
PCT/AU2005/000041 WO2005067959A1 (en) 2004-01-16 2005-01-14 Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion

Publications (1)

Publication Number Publication Date
BRPI0506916A true BRPI0506916A (pt) 2007-05-29

Family

ID=34795984

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506916-5A BRPI0506916A (pt) 2004-01-16 2005-01-14 modulação da chaperonina 10 da secreção de citocina e de quimiocina que pode ser induzida pelo receptor similar a toll

Country Status (11)

Country Link
US (2) US20070275890A1 (pt)
EP (1) EP1715884B1 (pt)
JP (1) JP2007517808A (pt)
KR (1) KR20060114011A (pt)
AT (1) ATE548047T1 (pt)
BR (1) BRPI0506916A (pt)
CA (1) CA2553325A1 (pt)
MX (1) MXPA06008082A (pt)
NZ (1) NZ548985A (pt)
RU (1) RU2446817C2 (pt)
WO (1) WO2005067959A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560436B2 (en) 2005-02-22 2009-07-14 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
JP2009500430A (ja) * 2005-07-11 2009-01-08 シーバイオ リミテッド シャペロニン１０により誘導される免疫調整方法
US7977458B2 (en) * 2005-08-31 2011-07-12 Cbio Limited Modified chaperonin 10
US7592003B2 (en) * 2005-09-30 2009-09-22 Oklahoma Medical Research Foundation Regulation of toll-like receptors on stem cells
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
US20090087410A1 (en) * 2005-10-20 2009-04-02 Cbio Limited Treatment of hypersensitivity
AU2013205017B2 (en) * 2006-03-02 2014-05-01 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
WO2007098557A1 (en) * 2006-03-02 2007-09-07 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
MX2010011169A (es) * 2008-04-11 2011-03-01 Cbio Ltd Cpn10 modificada y señalizacion de prr.
WO2009124333A1 (en) * 2008-04-11 2009-10-15 Cbio Limited Modified chaperonin 10 and prr signaling
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3987104B2 (ja) * 1993-11-30 2007-10-03 ザ・ユニバーシティ・オブ・クイーンズランド シャペロニン１０のアンタゴニスト
US6468536B1 (en) * 1996-09-18 2002-10-22 Zetesis S.P.A. Use of proteins as anti-diabetes agents
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AU2002952492A0 (en) * 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US20050208470A1 (en) * 2003-12-16 2005-09-22 University Of Massachusetts Toll-like receptor assays

Also Published As

Publication number Publication date
US20070275890A1 (en) 2007-11-29
WO2005067959A1 (en) 2005-07-28
RU2006129629A (ru) 2008-02-27
EP1715884B1 (en) 2012-03-07
JP2007517808A (ja) 2007-07-05
EP1715884A4 (en) 2009-09-09
CA2553325A1 (en) 2005-07-28
EP1715884A1 (en) 2006-11-02
ATE548047T1 (de) 2012-03-15
RU2446817C2 (ru) 2012-04-10
KR20060114011A (ko) 2006-11-03
US20090325882A1 (en) 2009-12-31
US7951613B2 (en) 2011-05-31
NZ548985A (en) 2010-02-26
MXPA06008082A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
BRPI0506916A (pt) modulação da chaperonina 10 da secreção de citocina e de quimiocina que pode ser induzida pelo receptor similar a toll
FI963101A0 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
CY1122238T1 (el) Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
CY1114919T1 (el) Anti-mag ανθρωποποιημενα αντισωματα και οι χρησεις τους για την αντιμετωπιση του εγκεφαλικου επεισοδιου
GEP20084325B (en) Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
MA38322A1 (fr) Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
MA31821B1 (fr) Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
DK0901374T3 (da) Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
ATE481424T1 (de) Il-17a- und il-17f-antagonisten und verwendungsverfahren
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
CY1113654T1 (el) Αρυλ ουριες ως αναστολεις κινασων
ATE540678T1 (de) Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
DE602005015002D1 (de) Methylendipiperidinderivate
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
RS20050616A (en) Pyrazoles and methods of making and using the same
CY1107005T1 (el) Ετεροπολυκυκλικες ενωσεις και οι χρησεις τους ως ανταγωνιστες των μεταβοτροπικων υποδοχέων του γλουταμικου
DE69935249D1 (de) Verwendung von at-1 rezeptorantagonisten oder at-2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
HK1112941A1 (en) Use of a33 antigens and jam-it a33
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
RU2010146161A (ru) Применение блокаторов интерферона типа i для профилактики и лечения псориаза
ATE399165T1 (de) Chinolinverbindungen und deren verwendungen
WO2001055107A3 (en) Aromatic amines and amides acting on the melanocortin receptors
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.